← All MEPs

Elena Yoncheva

European Parliament · ECR · 🇧🇬 Bulgaria

Term: since 18 July 2019

Participation in roll-call votes

65 % of the 2,540 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 0 % (0 / 5), presence 0 % (0 / 5) October 2019 : participation 100 % (19 / 19), presence 100 % (19 / 19) November 2019 : participation 100 % (18 / 18), presence 100 % (18 / 18) December 2019 : participation 100 % (6 / 6), presence 100 % (6 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 100 % (8 / 8), presence 100 % (8 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 100 % (19 / 19), presence 100 % (19 / 19) September 2020 : participation 100 % (24 / 24), presence 100 % (24 / 24) October 2020 : participation 97 % (36 / 37), presence 97 % (36 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 97 % (29 / 30), presence 97 % (29 / 30) January 2021 : participation 91 % (21 / 23), presence 91 % (21 / 23) 2021 February 2021 : participation 95 % (20 / 21), presence 95 % (20 / 21) March 2021 : participation 97 % (30 / 31), presence 97 % (30 / 31) April 2021 : participation 99 % (80 / 81), presence 99 % (80 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 97 % (28 / 29), presence 97 % (28 / 29) July 2021 : participation 96 % (26 / 27), presence 96 % (26 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 93 % (25 / 27), presence 93 % (25 / 27) December 2021 : participation 93 % (27 / 29), presence 93 % (27 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 100 % (37 / 37), presence 100 % (37 / 37) April 2022 : participation 0 % (0 / 22), presence 0 % (0 / 22) May 2022 : participation 68 % (60 / 88), presence 68 % (60 / 88) June 2022 : participation 43 % (20 / 46), presence 43 % (20 / 46) July 2022 : participation 87 % (27 / 31), presence 87 % (27 / 31) September 2022 : participation 0 % (0 / 25), presence 0 % (0 / 25) October 2022 : participation 34 % (11 / 32), presence 34 % (11 / 32) November 2022 : participation 89 % (34 / 38), presence 89 % (34 / 38) December 2022 : participation 94 % (17 / 18), presence 94 % (17 / 18) January 2023 : participation 50 % (8 / 16), presence 50 % (8 / 16) 2023 February 2023 : participation 69 % (20 / 29), presence 69 % (20 / 29) March 2023 : participation 62 % (18 / 29), presence 62 % (18 / 29) April 2023 : participation 0 % (0 / 24), presence 0 % (0 / 24) May 2023 : participation 84 % (78 / 93), presence 84 % (78 / 93) June 2023 : participation 50 % (20 / 40), presence 50 % (20 / 40) July 2023 : participation 0 % (0 / 40), presence 0 % (0 / 40) September 2023 : participation 70 % (19 / 27), presence 70 % (19 / 27) October 2023 : participation 28 % (11 / 40), presence 28 % (11 / 40) November 2023 : participation 53 % (28 / 53), presence 53 % (28 / 53) December 2023 : participation 0 % (0 / 40), presence 0 % (0 / 40) January 2024 : participation 0 % (0 / 49), presence 0 % (0 / 49) 2024 February 2024 : participation 59 % (37 / 63), presence 59 % (37 / 63) March 2024 : participation 66 % (33 / 50), presence 66 % (33 / 50) April 2024 : participation 43 % (92 / 213), presence 43 % (92 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 0 % (0 / 8), presence 0 % (0 / 8) October 2024 : participation 38 % (5 / 13), presence 38 % (5 / 13) November 2024 : participation 78 % (21 / 27), presence 78 % (21 / 27) December 2024 : participation 0 % (0 / 18), presence 0 % (0 / 18) January 2025 : participation 0 % (0 / 6), presence 0 % (0 / 6) 2025 February 2025 : participation 40 % (4 / 10), presence 40 % (4 / 10) March 2025 : participation 86 % (12 / 14), presence 86 % (12 / 14) April 2025 : participation 100 % (22 / 22), presence 100 % (22 / 22) May 2025 : participation 65 % (35 / 54), presence 65 % (35 / 54) June 2025 : participation 0 % (0 / 22), presence 0 % (0 / 22) July 2025 : participation 88 % (28 / 32), presence 88 % (28 / 32) September 2025 : participation 83 % (24 / 29), presence 83 % (24 / 29) October 2025 : participation 60 % (27 / 45), presence 60 % (27 / 45) November 2025 : participation 92 % (47 / 51), presence 92 % (47 / 51) December 2025 : participation 35 % (11 / 31), presence 35 % (11 / 31) January 2026 : participation 100 % (22 / 22), presence 100 % (22 / 22) 2026 February 2026 : participation 86 % (24 / 28), presence 86 % (24 / 28) March 2026 : participation 68 % (30 / 44), presence 68 % (30 / 44) April 2026 : participation 0 % (0 / 51), presence 0 % (0 / 51) May 2026 : participation 52 % (13 / 25), presence 52 % (13 / 25) June 2026 : participation 63 % (22 / 35), presence 63 % (22 / 35) July 2026 : participation 60 % (21 / 35), presence 60 % (21 / 35) September 2026 : participation 55 % (22 / 40), presence 55 % (22 / 40) October 2026 : participation 49 % (26 / 53), presence 49 % (26 / 53) November 2026 : participation 92 % (12 / 13), presence 92 % (12 / 13)

Their votes

2,540 votes

DateTextResultTheir vote
Implementation of the common commercial policy – annual report 2018 For
The Establishment of an EU Mechanism on Democracy, the Rule of Law and Fundamental Rights For
The European Year of Greener Cities 2022 For
COVID-19: EU coordination of health assessments and risk classification, and the consequences for Schengen and the single market For
The cultural recovery of Europe For
The draft Commission regulation amending Annexes II, III and IV to Regulation (EC) No 396/2005 as regards maximum residue levels for cycloxydim, flonicamid, haloxyfop, mandestrobin, mepiquat, Metschnikowia fructicola strain NRRL Y-27328 and prohexadione in or on certain products For
Measures for a sustainable rail market in view of the COVID-19 pandemic For
The humanitarian situation in Mozambique For
The case of Dr. Denis Mukwege in the Democratic Republic of the Congo (DRC) For
The situation in the Philippines, including the case of Maria Ressa For
Resolution on the situation in Russia: the poisoning of Alexei Navalny For
The situation in Belarus For
The preparation of the special European Council summit focusing on the dangerous escalation and the role of Turkey in the Eastern Mediterranean For
Report on the implementation of National Roma Integration Strategies: Combating negative attitudes towards people with Romani background in Europe For
Shortage of medicines - how to address an emerging problem For
Maximising the energy efficiency potential of the EU building stock For
A strategic approach to pharmaceuticals in the environment For
Determination of a clear risk of a serious breach by Poland of the rule of law For
Annual report on arms export For
Just Transition Fund For
Real Driving Emissions  (RDE) For
Annual implementing report on the EU association agreement with Georgia For
Carbon dioxide emissions from maritime transport: global data collection system for ship fuel oil consumption data For
Union Civil Protection Mechanism For
EU-African security cooperation in the Sahel region, West Africa and the Horn of Africa For
The EU’s role in protecting and restoring the world’s forests For
The conclusions of the extraordinary European Council meeting of 17-21 July 2020 For
Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or pent coronavirus disease For
Emission limits and type-approval for internal combustion engines for non-road mobile machinery: transitional provisions in order to address the impact of COVID-19 crisis For
The revision of the guidelines for trans-European energy infrastructure For
The EU’s public health strategy post-COVID-19 For
A comprehensive Union policy on preventing money laundering and terrorist financing – the Commission’s Action Plan and other recent developments For
The Chemicals Strategy for Sustainability For
European Parliament recommendation to the Council and the Commission concerning the conclusion of an agreement, under negotiation, between the European Union and New Zealand on the exchange of personal data between the European Union Agency for Law Enforcement Cooperation (Europol) and the New Zealand authorities competent for fighting serious crime and terrorism For
A comprehensive European approach to energy storage For
The draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, dimethomorph, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, formetanate, metribuzin, milbemectin… For
Objection pursuant to Rule 112(2) and (3): Certain uses of chromium trioxide For
Mobilisation of the Contingency Margin in 2020: continuation of humanitarian support to refugees in Turkey For
Amending budget 5/2020: continuation of the support to refugees and host communities in response to the Syria crisis in Jordan, Lebanon and Turkey For
Guidelines for the employment policies of the Member States For

Rows per page: 20 40 100 200 All